Stocks and Investing
Stocks and Investing
Mon, December 10, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, December 7, 2018
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joel Beatty Maintained (VNDA) at Strong Buy with Increased Target to $47 on, Dec 7th, 2018
Joel Beatty of Citigroup, Maintained "Vanda Pharmaceuticals Inc." (VNDA) at Strong Buy with Increased Target from $31 to $47 on, Dec 7th, 2018.
Joel has made no other calls on VNDA in the last 4 months.
There are 3 other peers that have a rating on VNDA. Out of the 3 peers that are also analyzing VNDA, 0 agree with Joel's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Joel
- Charles Duncan of "Cantor Fitzgerald" Upgraded from Hold to Buy and Held Target at $43 on, Tuesday, December 4th, 2018
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $26 on, Thursday, November 8th, 2018
- Derek Archila of "Oppenheimer" Maintained at Buy with Increased Target to $29 on, Friday, September 21st, 2018